Thyroid hormones and cancer: Clinical studies of hypothyroidism in oncology

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 5, 2010, Pages 432-436

  Hercbergs, Aleck H ^a   Ashur Fabian, Osnat ^b   Garfield, David ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MEIR MEDICAL CENTER   (Israel)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

cancer; hypothyroxinemia; integrin avb3; L thyroxine; triiodothyronine

Indexed keywords

THYROID HORMONE; THYROTROPIN;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DIET SUPPLEMENTATION; DISEASE COURSE; GLIOBLASTOMA; GLIOMA; HORMONAL THERAPY; HORMONE METABOLISM; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; HYPOTHYROXINEMIA; NEOPLASM; NONHUMAN; PANCREAS CANCER; POSTMENOPAUSE; REVIEW; THYROID DISEASE;

ANIMALS; ANTITHYROID AGENTS; CELL PROLIFERATION; FEMALE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INTEGRIN ALPHAVBETA3; NEOPLASMS; PROPYLTHIOURACIL; RATS; RECEPTORS, THYROID HORMONE; RISK FACTORS; THYROID HORMONES;

EID: 77956266913     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833d9710     Document Type: Review

References (46)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 2:104-107.
2. Hercbergs A, Leith JT. Spontaneous remission of metastatic lung cancer following myxedema coma: an apoptosis-related phenomenon? J Natl Cancer Inst 1993; 85:1342-1343.
3. Shoemaker JP, Dagher RK. Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. J Natl Cancer Inst 1977; 62:1575-1578.
4. Kumar MS, Chiang T, Deodhar SD. Enhancing effect of thyroxine on tumor growth and metastasis in syngeneic mouse tumor systems. Cancer Res 1979; 39:3515-3518.
5. Mishkin SY, Pollak R, Yalovsky MA, et al. Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroid-ism. Cancer Res 1981; 41:3040-3045.
6. Theodossiou C, Skrepnik N, Robert EG, et al. Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 1999; 86:1596-1601.
7. Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia: a novel paradigm. In Vivo 1996; 10:245-247.
8. Bergh JJ, Lin H-Y, Lansing L, et al. Integrin avb3 contains a cell surface receptor site for thyroid hormone that is linked to activation of MAPK and induction of angiogenesis. Endocrinology 2005; 146:2864-2871.
9. Cheng SY, Leonard LJ, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010; 31:139-170.
10. Guernsey DL, Ong A, Borek C. Thyroid hormone modulation of X-ray-induced in vitro neoplastic transformation. Nature (London) 1980; 288: 591-592.
11. Borek C, Guernsey DL, Ong A, Edelman IS. Critical role played by thyroid hormone in induction of neoplastic transformation by chemical carcinogens in tissue culture. Proc Natl Acad Sci\USA 1983; 80:5749-5752.
12. Goodman AD, Hoekstra SJ, Marsh PS. Effects of hypothyroidism on the induction and growth of mammary cancer induced by 7,12-dimethylben-z(a) anthracene in the rat. Cancer Res 1980; 40:2336-2342.
13. Feng X, Jiang Y, Meltzer P, Yen PM. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol 2000; 14:947-955.
14. Miller LD, McPhie P, Suzuki H, et al. Multitissue gene expression analysis in a mouse model of thyroid hormone resistance. Genome Biol 5:R31.
15. Lin HY, Sun M, Tang HY, et al. L-Thyroxine vs. 3, 5 3-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009; 296:C980-C991.
16. Yalcin M, Dyskin E, Lansing L, et al. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 2010; 95:1972-1980.
17. Yalcin M, Bharali DJ, Lansing L, et al. Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 2009; 29:3825-3831.
18. Hellevik AI, Asvold BO, Bjøro T, et al. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 2009; 18:570-574.
19. Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000; 11:111-117.
20. Hoffman DA, McConahey WM, Brinton LA, et al. Breast cancer in hypothyroid women using thyroid supplements. JAMA 1984; 251:616-619.
21. Saraiva PP, Figueirado NB, Padovani CR, et al. Profile of thyroid hormones in breast cancer patients. Braz J Med Res 2005; 38:761-765.
22. Ko AH, Wang F, Holly EA. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control 2007; 18:809-819.
23. Rosenberg AG, Dexeus F, Swanson DA, et al. Relationship of thyroid disease to renal cell carcinoma: an epidemiologic study. Urology 1990; 35:492-498.
24. Cristofanilli M, Yamamura Y, Kau S-W, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005; 103:1122-1128.
25. Backwinkel K, Jackson A. Some features of breast cancer and thyroid deficiency. Cancer 1964; 17:1174-1176.
26. Hercbergs AH, Daw H, Thakur S. Primary hypothyroidism and breast cancer: clinical and pathological risk reduction correlates from a case control study. Proceedings of the 80th Annual Meeting of the American thyroid Association; Palm Beach, Florida, poster no.178; 2009.
27. Hercbergs A, Mason J, Reddy C. Thyroid hormones and lung cancer: primary hypothyroidism is prognostically significant for survival in lung cancer [abstract #4440]. 95th Annual Meeting, AACR; Orlando, FL; 30 March 2004.
28. Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotrophin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87:3221-3226.
29. Illouz F, Laboureau-Soares S, Dubois S. Tyrosine kinase inhibitors and modifications of thyroid function. Euro J Endocrinol 2009; 160:331-336.
30. Sabatier R, Gravis G, Deville, J. Hypothyroidism and survival during sunitinib therapy in metastatic renal cell cancer: a prospective observational analysis [abstract # 317]. ASCO Genitourinary Cancers Symposium; 2009.
31. Hercbergs A. Hypothyroidism and tumor regression. N Engl J Med 1988; 319:1315.
32. Hercbergs A. High tumor response rate to radiation therapy in biochemically hypothyroid patients [abstract #167]. Proceedings of AACR; 1997. p. 248.
33. Hercbergs A. Spontaneous remission of cancer: a thyroid hormone dependent phenomenon? Anticancer Res 1999; 19:4839-4844.
34. Hercbergs A, Daw H, Ayoub W. Possible association of hypothyroidism with longevity in advanced colorectal and pancreatic cancer: a case study. 79th Annual Meeting of American Thyroid Association; Chicago, IL; October 2008. Thyroid 2008; 8:S-18.
35. Nelson M, Hercbergs A, Rybicki L, et al. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132:1041-1046.
36. Smith GL, Smith BD, Gardes AS. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck 2009; 31:1031-1038.
37. Burt JRF, Schapira DV. Thyroid hormone: a modifier of the natural history of breast cancer [abstract no. 738]. Annual Meeting of the American Association for Cancer Research; 1983.
38. Kapdi CC, Wolfe JN, Shapiro S, et al. Breast cancer. Relationship to thyroid supplements for hypothyroidism. JAMA 1976; 236:1124-1127.
39. Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318:1557-1563.
40. Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunother-apy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11:1376-1383.
41. Hercbergs A, Goyal LK, Suh JH, et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003; 23 (1B):617-626.
42. Hercbergs A, Suh J, Reddy C, Goyal L. Early onset propylthiouracil- induced hypothyroidism is associated with improved survival in recurrent high grade glioma [abstract #1211]. 99th Annual meeting AACR; San Diego, CA; April 2008.
43. Linetsky E, Hercbergs A, Dotan S, et al. Time to tumor progression (TTP) and quality of life (QOL) following propylthiouracil induction of chemical hypothyr-oidism in failed malignant gliomas [abstract no. 144]. World Federation of Neuro-Oncology-Second Quadrennial Meeting; Edinburgh; 5 May 2005. p. 40.
44. Hercbergs A, Setrakian S, Abdelmannan D. Anaplastic thyroid CA: 10-year survival in a man with uncorrected primary hypothyroidism. Thyroid 2007; 17 (Suppl 1):S-93.
45. Surks MI, Ortiz E, Daniels GH. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291:228-238.
46. Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005; 90:581-585.